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background:  In the PLATO trial ticagrelor was superior to clopidogrel in reducing ischemic outcome and death in patients with acute coronary 
syndromes (ACS). Ticagrelor is a direct-acting P2Y12 receptor antagonist that is rapidly absorbed and partly metabolized to the major metabolite 
AR-C124910XX (ARC). ARC is also active, and has plasma concentrations approximately one third that of ticagrelor.
methods: We performed a genome wide association study to identify single nucleotide polymorphisms (SNPs) associated with plasma levels of 
ticagrelor and ARC, after 90 mg ticagrelor twice-daily, in 3751 PLATO patients. The steady-state area under the curve (AUCss) values estimated by the 
population pharmacokinetic models were log transformed and analyzed on a genome-wide scale using linear regression. SNPs were analyzed against 
clinical events using Cox-regression in 4990 patients.
results: A SNP (rs113681054) in SLCO1B1 was associated with levels of ticagrelor (P=1.1x10-6) and ARC (P=4.6x10-13). This SNP is in linkage 
disequilibrium with a functional variant (rs4149056) that results in decreased OATP1B1 transporter activity. Ticagrelor levels were also associated 
with two independent SNPs (rs62471956, P=7.7x10-15 and rs56324128, P=9.7x10-12) in the CYP3A4 region. Furthermore, ARC levels were 
associated with rs61361928 (P=3.0x10-14) in UGT2B7. None of the identified SNPs that affected ticagrelor or ARC pharmacokinetics (PK) were 
associated with the primary composite outcome of PLATO (myocardial infarction, cardiovascular death and stroke: rs4149056: HR 0.99 (95% CI: 
0.83-1.18) p=0.9), non-CABG major/minor bleeds or investigator reported dyspnea event.
conclusion: Despite the associations between the three genes SLCOB1, UGT2B7 and CYP3A4 and ticagrelor PK, these phenomena did not 
translate into any detectable effect on efficacy or safety during ticagrelor treatment.
